LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 43

Search options

  1. Article ; Online: Acute promyelocytic leukemia: if you wait it is too late.

    Ammatuna, Emanuele / van Doesum, Jaap

    Leukemia & lymphoma

    2021  Volume 62, Issue 6, Page(s) 1538

    MeSH term(s) Animals ; Humans ; Leukemia, Promyelocytic, Acute/diagnosis ; Oncogene Proteins, Fusion/genetics ; Reverse Transcriptase Polymerase Chain Reaction
    Chemical Substances Oncogene Proteins, Fusion
    Language English
    Publishing date 2021-01-06
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2020.1869227
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: High frequency of hyperglycaemia observed during CAR T-cell treatment.

    Tienstra, Marieke / de Boer, Janneke W / van Doesum, Jaap A / van Meerten, Tom / van Dijk, Peter R

    Diabetic medicine : a journal of the British Diabetic Association

    2022  Volume 40, Issue 2, Page(s) e14969

    MeSH term(s) Humans ; Hyperglycemia/epidemiology ; T-Lymphocytes
    Language English
    Publishing date 2022-10-17
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 605769-x
    ISSN 1464-5491 ; 0742-3071 ; 1466-5468
    ISSN (online) 1464-5491
    ISSN 0742-3071 ; 1466-5468
    DOI 10.1111/dme.14969
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1954: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Nieuwe hoop voor patiënten met uitbehandelde lymfeklierkanker.

    van Doesum, Jaap A / Niezink, Anne G H / van Meerten, Tom

    Nederlands tijdschrift voor geneeskunde

    2021  Volume 165

    Abstract: The prognosis of patients with diffuse large B-cell lymphoma a primary refractory disease or relapsed within 12 months after autologous hematopoietic cell transplantation is poor with a median survival of only 6 months. With the new CD19-directed CAR T- ... ...

    Title translation New treatment for patients with therapy-resistant lymphoma: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy.
    Abstract The prognosis of patients with diffuse large B-cell lymphoma a primary refractory disease or relapsed within 12 months after autologous hematopoietic cell transplantation is poor with a median survival of only 6 months. With the new CD19-directed CAR T-cell therapy, 40% of the patients still achieve a long-term remission. However, this new treatment does bring new challenges such as bridging the time during the CAR T-cell product time, and recognition of treatment-related side effects such as cytokine release syndrome or neurotoxicity. Therefore, treatment by a dedicated, multidisciplinary team is necessary. Future research will focus on extending CAR T-cell therapy to other diseases and improve treatment in non-responsiveness or resistance to CAR-T cell therapy.
    MeSH term(s) Antigens, CD19 ; Cell- and Tissue-Based Therapy ; Humans ; Immunotherapy, Adoptive ; Lymphoma, Large B-Cell, Diffuse ; Receptors, Chimeric Antigen
    Chemical Substances Antigens, CD19 ; Receptors, Chimeric Antigen
    Language Dutch
    Publishing date 2021-08-19
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 82073-8
    ISSN 1876-8784 ; 0028-2162
    ISSN (online) 1876-8784
    ISSN 0028-2162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.18: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma.

    Keijzer, Kylie / de Boer, Janneke W / van Doesum, Jaap A / Noordzij, Walter / Huls, Gerwin A / van Dijk, Lisanne V / van Meerten, Tom / Niezink, Anne G H

    Blood cancer journal

    2024  Volume 14, Issue 1, Page(s) 41

    Abstract: Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV and MATV- ... ...

    Abstract Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV and MATV-dynamics, between pre-apheresis (baseline) and pre-lymphodepleting chemotherapy (pre-LD) MATV, on CAR T-cell outcomes and toxicities in patients with r/r LBCL. MATVs were calculated semi-automatically at baseline (n = 74) and pre-LD (n = 68) in patients with r/r LBCL who received axicabtagene ciloleucel. At baseline, patients with a low MATV (< 190 cc) had a better time to progression (TTP) and overall survival (OS) compared to high MATV patients (p < 0.001). High MATV patients who remained stable or reduced upon bridging therapy showed a significant improvement in TTP (p = 0.041) and OS (p = 0.015), compared to patients with a high pre-LD MATV (> 480 cc). Furthermore, high MATV baseline was associated with severe cytokine release syndrome (CRS, p = 0.001). In conclusion, patients with low baseline MATV had the best TTP/OS and effective reduction or controlling MATV during bridging improved survival outcomes in patients with a high baseline MATV, providing rationale for the use of more aggressive bridging regimens.
    MeSH term(s) Humans ; Tumor Burden ; Lymphoma, Large B-Cell, Diffuse/therapy ; Adaptor Proteins, Signal Transducing ; Antigens, CD19 ; T-Lymphocytes
    Chemical Substances Adaptor Proteins, Signal Transducing ; Antigens, CD19
    Language English
    Publishing date 2024-03-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-024-01022-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Semi-automated

    Keijzer, Kylie / Niezink, Anne G H / de Boer, Janneke W / van Doesum, Jaap A / Noordzij, Walter / van Meerten, Tom / van Dijk, Lisanne V

    Computational and structural biotechnology journal

    2023  Volume 21, Page(s) 1102–1114

    Abstract: In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be a prognostic factor in NHL. It is ... ...

    Abstract In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be a prognostic factor in NHL. It is usually retrieved using semi-automated thresholding methods based on standardized uptake values (SUV), calculated from
    Language English
    Publishing date 2023-01-20
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2694435-2
    ISSN 2001-0370
    ISSN 2001-0370
    DOI 10.1016/j.csbj.2023.01.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands.

    van Doesum, Jaap / Chinea, Anabelle / Pagliaro, Maria / Pasquini, Maria Cristina / van Meerten, Tom / Bakker, Martijn / Ammatuna, Emanuele

    Leukemia

    2020  Volume 34, Issue 9, Page(s) 2536–2538

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Hematologic Diseases ; Hematologic Neoplasms ; Humans ; Italy ; Netherlands ; Pandemics ; Pneumonia, Viral ; Retrospective Studies ; SARS-CoV-2 ; Spain
    Keywords covid19
    Language English
    Publishing date 2020-07-08
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-020-0960-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2295: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.

    de Boer, Janneke W / Pennings, Elise R A / Kleinjan, Ankie / van Doesum, Jaap A / Spanjaart, Anne M / Mutsaers, Pim G N J / Jak, Margot / van der Poel, Marjolein W M / Kuipers, Maria T / Adam, Judit A / Diepstra, Arjan / Koens, Lianne / van Dorp, Suzanne / Vermaat, Joost S P / Niezink, Anne G H / Kersten, Marie José / van Meerten, Tom

    Blood advances

    2023  Volume 7, Issue 21, Page(s) 6710–6716

    MeSH term(s) Humans ; Fluorodeoxyglucose F18 ; Positron Emission Tomography Computed Tomography ; Immunotherapy, Adoptive ; Neoplasm Recurrence, Local/diagnostic imaging ; Lymphoma/therapy ; Antigens, CD19
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; Antigens, CD19
    Language English
    Publishing date 2023-08-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023010665
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment.

    van Doesum, Jaap A / Niezink, Anne G H / Huls, Gerwin A / Beijert, Max / Diepstra, Arjan / van Meerten, Tom

    HemaSphere

    2021  Volume 5, Issue 2, Page(s) e523

    Abstract: The aggressive lymphoma, extranodal natural killer/T-cell lymphoma-nasal type, is strongly associated with Epstein-Barr virus (EBV) and is most common in Asia and in South and Central America. By contrast, incidence is low in the United States and Europe, ...

    Abstract The aggressive lymphoma, extranodal natural killer/T-cell lymphoma-nasal type, is strongly associated with Epstein-Barr virus (EBV) and is most common in Asia and in South and Central America. By contrast, incidence is low in the United States and Europe, where extranodal natural killer/T-cell lymphoma represents only 0.2%-0.4% of all newly diagnosed non-Hodgkin lymphomas. At diagnosis, it is important to test for EBV DNA in plasma by polymerase chain reaction and to carry out positron emission tomography/computer tomography and magnetic resonance imaging of the nasopharynx. In stage I/II disease, radiotherapy is the most important treatment modality, but in high-risk stage I/II disease (stage II, age > 60 y, elevated lactate dehydrogenase, Eastern Cooperative Oncology Group performance score ≥2, primary tumor invasion), it should be combined with chemotherapy. The most optimal responses are reached with nonmultidrug resistance-based therapy (eg, asparaginase- or platinum-based therapy). Therapeutic approaches consist of either platinum-based concurrent chemoradiotherapy or sequential chemoradiotherapy. The minimum dose of radiotherapy should be 50-56 Gy. Treatment of stage III/IV disease consists of 3 cycles of chemotherapy followed by autologous hematopoietic cell transplantation. Allogeneic hematopoietic cell transplantation should only be considered in case of relapsed disease or after difficulty reaching complete remission. During treatment and follow-up, plasma EBV levels should be monitored as a marker of tumor load.
    Language English
    Publishing date 2021-01-12
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2572-9241
    ISSN (online) 2572-9241
    DOI 10.1097/HS9.0000000000000523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article: Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.

    de Boer, Janneke W / Keijzer, Kylie / Pennings, Elise R A / van Doesum, Jaap A / Spanjaart, Anne M / Jak, Margot / Mutsaers, Pim G N J / van Dorp, Suzanne / Vermaat, Joost S P / van der Poel, Marjolein W M / van Dijk, Lisanne V / Kersten, Marie José / Niezink, Anne G H / van Meerten, Tom

    Cancers

    2023  Volume 15, Issue 22

    Abstract: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can hamper the clinical benefit of CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL). To assess the risk of CRS and ... ...

    Abstract Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can hamper the clinical benefit of CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL). To assess the risk of CRS and ICANS, the endothelial activation and stress index (EASIX), the modified EASIX (m-EASIX), simplified EASIX (s-EASIX), and EASIX with CRP/ferritin (EASIX-F(C)) were proposed. This study validates these scores in a consecutive population-based cohort. Patients with r/r LBCL treated with axicabtagene ciloleucel were included (
    Language English
    Publishing date 2023-11-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15225443
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands

    van Doesum, Jaap / Chinea, Anabelle / Pagliaro, Maria / Pasquini, Maria Cristina / van Meerten, Tom / Bakker, Martijn / Ammatuna, Emanuele

    Leukemia

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #638586
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top